Molecular pathologies of and enzyme replacement therapies for lysosomal diseases.
Lysosomal diseases comprise a group of inherited disorders resulting from defects of lysosomal enzymes and their cofactors, and in many of them the nervous system is affected. Recently, enzyme replacement therapy with recombinant lysosomal enzymes has been clinically available for several lysosomal diseases. Such enzyme replacement therapies can improve non-neurological disorders but is not effective for neurological ones. In this review, we discuss the molecular pathologies of lysosomal diseases from the protein structural aspect, current enzyme replacement therapies, and attempts to develop enzyme replacement therapies effective for lysosomal diseases associated with neurological disorders, i.e., production of enzymes, brain-specific delivery and incorporation of lysosomal enzymes into cells.
Sakuraba
Hitoshi
H
CREST, JST, Kawaguchi, Japan. sakuraba@rinshoken.or.jp
Sawada
Makoto
M
Matsuzawa
Fumiko
F
Aikawa
Sei-ichi
S
Chiba
Yasunori
Y
Jigami
Yoshifumi
Y
Itoh
Kohji
K
D000818:Animals; D017077:Culture Media, Conditioned / Q000494:pharmacology; D057487:Enzyme Therapy; D004798:Enzymes / Q000737:chemistry / Q000235:genetics; D005678:G(M2) Ganglioside / Q000378:metabolism; D006801:Humans; D020140:Lysosomal Storage Diseases, Nervous System / Q000201:enzymology* / Q000235:genetics / Q000628:therapy; D008247:Lysosomes / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000235:genetics / Q000627:therapeutic use*; D012497:Sandhoff Disease / Q000201:enzymology / Q000235:genetics / Q000503:physiopathology; D013661:Tay-Sachs Disease / Q000201:enzymology / Q000235:genetics / Q000503:physiopathology; D001619:beta-N-Acetylhexosaminidases / Q000737:chemistry / Q000235:genetics
D017077:Culture Media, Conditioned; D004798:Enzymes; D011993:Recombinant Fusion Proteins; D005678:G(M2) Ganglioside; D001619:beta-N-Acetylhexosaminidases